As per Triton's research report, the Middle East and African immunosuppressant drugs market is anticipated to upsurge with a CAGR of 5.59% in the forecasting years of 2019-2028.
The countries reviewed in this market are:
• The UAE
• Turkey
• South Africa
• Saudi Arabia
• Rest of MEA
More than 500,000 people have pledged organ donation in Turkey, owing to the increasing awareness created by campaigns organized in the National Organ Donation Week. In 2019, doctors in the country performed 4,710 organ transplant procedures across 148 transplantation centers. It holds the record for the largest number of transplants performed in the Middle East region. Living donors are the source of 75% of the donors; whereas, the remaining are harvested from cadavers. The Turkish Transplant Coordinators Association states that, it is among the top three nations in the world in terms of live transplants. 29,000 patients in the country are on the waiting lists for organ replacement. Immunosuppressants are given to patients after they undergo an organ transplant. Thus, the increasing number of transplantations being carried out in the country are raising the demand for immunosuppressant drugs. This is leading to the growth of the studied market in Turkey over the forecast period.
Organ transplant procedures are being carried out in Saudi Arabia since 1979. Initially, these procedures were limited to only renal transplants. Gradually, cardiac transplantation and liver transplantation were introduced. With technological advancements, the country also picked pace, matching the levels of other nations. Currently, there are 12 transplant programs for kidneys, 3 for liver, 2 for lungs, 2 for pancreas, and 1 for cardiac problems throughout the nation. Also, tissue transplants, such as those for cornea, heart valves, and bone, are being offered. Thus, the growing demand for organ transplantation is fueling the growth of the immunosuppressant drugs market in the KSA.
Bristol-Myers Squibb Company's biopharmaceutical segment discovers, develops, licenses, manufactures, markets, distributes and sells innovative medicines to help patients prevail over serious diseases. NULOJIX, AZACTAM, BARACLUDE, COUMADIN, and ELIQUIS are the immunosuppressant drugs manufactured by the company. Bristol-Myers has a notable presence in the Middle East and Africa.
The top key players in the immunosuppressant drugs market are Pfizer Inc, Janssen Pharmaceuticals Inc (Johnson & Johnson Services Inc), Veloxis Pharmaceuticals Inc, Intas Pharmaceuticals Ltd (Accord Healthcare), Dr Reddys Laboratories Ltd, Cipla Ltd, GlaxoSmithKline plc, F Hoffmann-La Roche Ltd, Mylan NV, Novartis AG, Astellas Pharma Inc, Allergan (acquired by Abbvie Inc), Abbvie Inc, Bristol-Myers Squibb Company, and Sanofi.